| アブストラクト | INTRODUCTION: This study aimed to assess the association between pharmacotherapy and secondary hip fracture incidence. MATERIALS AND METHODS: The correlation between secondary hip fracture incidence and the presence, type, and medication possession ratio (MPR) of pharmacotherapy was investigated using medical insurance data acquired from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. RESULTS: Data collected from female patients (n = 1,435,347) were analyzed. The 2-year secondary hip fracture incidence was 3.48% (n = 49,921). Secondary hip fracture was significantly more common in patients without medications (3.80%) than in those with medications (3.00%). Patients receiving selective estrogen receptor modulators (SERMs) had the lowest average age. The crude incidence of secondary hip fracture was the lowest in patients receiving SERMs (n = 2088 [2.52%]), followed by those taking bisphosphonates (n = 11,355 [2.88%]), denosumab (n = 1118 [2.90%]), no medications (n = 32,747 [3.80%]), and parathyroid hormone (PTH: n = 2163 [4.55%]), whereas the age-adjusted incidence was the lowest in patients administered denosumab (2.27%), followed by those taking bisphosphonates (2.47%), SERMs (2.55%), PTH (3.67%), and no medications (3.80%). The mean MPR was the highest in patients taking denosumab (64.9%), followed by those receiving bisphosphonates (58.7%), SERMs (58.2%), and PTH (40.6%) in the no hip fracture group. CONCLUSION: Secondary hip fractures were less likely to occur with medication versus no medication. Differences in the crude incidence of secondary hip fracture based on medications usage might be attributed to background characteristics. |
|---|
| 組織名 | Department of Orthopedic Surgery, Asahi General Hospital, 477 Tomari, Asahimachi,;Shimo-Niikawa-gun, Toyama, 939-0798, Japan. nakato38@cosmo21.net.;National Database Japan-Osteoporosis Management Study Group, Department of Public;Health, Kindai University Faculty of Medicine, 377-2 Oono-higashi, Osaka-Sayama,;Osaka, 589-8511, Japan. nakato38@cosmo21.net.;Department of Health Administration and Policy, Tohoku University School of;Medicine, 2-1 Seiryo-Machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.;Osaka, 589-8511, Japan.;Department of Regulatory Science, School of Pharmacy, Tokyo University of;Pharmacy and Life Sciences, HorinouchiTokyo, Hachiouji, 1432-1192-0392, Japan.;Department of Hygiene and Public Health, Osaka Medical and Pharmaceutical;University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.;Okimoto Clinic, 185-4, Kubi, Yutaka-machi, Kure-City, Hiroshima, 734-0304, Japan.;Department of Geriatric Medicine, Graduate School of Medicine, The University of;Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.;Department of Public Health, Kindai University Faculty of Medicine, 377-2,;Oono-Higashi, Osaka-Sayama City, Osaka, 589-8511, Japan. |
|---|
